Amplify Weight Loss Drug & Treatment ETF
THNRNYSEARCAAmplify InvestmentsEquity
As of Oct 16, 2026 close
- Assets (AUM)
- $5.64M
- Expense ratio
- 0.59%
- Dividend yield
- 1.67%
- Holdings
- 23
- 52-week range
- $22.89$27.94
- Volume (live)
- -
- Avg. volume (3M)
- 717
THNR ETF: Amplify Weight Loss Drug & Treatment ETF - Price, Holdings & Analysis
Amplify Weight Loss Drug & Treatment ETF Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fund characteristics, expense ratio, dividend yield, and performance metrics
| Day's Range | $24.51 - $24.74 |
|---|---|
| 52-Week High | $27.94 |
| 52-Week Low | $22.89 |
| Open | $24.74 |
| Volume (last close) | 664 |
| Average Volume (3M) | 717 |
| 1 Day Change | +2.38% |
|---|---|
| 1 Month Change | −2.84% |
| 6 Month Change | −1.24% |
| YTD Change | −2.67% |
| 1 Year Change | +5.91% |
| Annual Dividend | $0.41 |
|---|---|
| Dividend Yield | 1.67% |
| Last Dividend Ex-Date | Dec 30, 2025 |
| Dividend Growth YoY | +87.80% |
| Years Dividend Growth | 1 |
| Assets (AUM) | $5.64M |
|---|---|
| Expense Ratio | 0.59% |
| Total Holdings | 23 |
| Inception Date | May 20, 2024 |
| 50-Day MA | $25.96 |
|---|---|
| 200-Day MA | $25.38 |
| RSI | 35.06 |
| Stochastic %K | 30.42 |
| Stochastic %D | 28.98 |
Source: Exchange price data and fund disclosures. Data as of Oct 16, 2026. Data sources and methodology
THNR at a Glance
Amplify Weight Loss Drug & Treatment ETF (THNR) is an equity ETF from Amplify Investments, launched in May 2024. It manages $5.64M in assets and charges a 0.59% expense ratio, about $59 a year per $10,000 invested.
As of its Oct 4, 2026 holdings, it holds 23 positions. The largest are Eli Lilly and Company (LLY, 10.19%), Novo Nordisk A/S (NVO, 8.45%) and CSPC Pharmaceutical Group Limited (HKG:1093, 5.92%). The top 10 holdings make up 62.4% of the fund. By sector it leans toward Healthcare (100.0%). Its largest country exposures are United States (51.4%), Denmark (16.2%) and Japan (11.4%).
It pays distributions yielding 1.67% at the Oct 16, 2026 close, $0.41 per share over the trailing 12 months. As of the Oct 16, 2026 close, the share price is up 5.9% over one year (price change, excluding distributions).
Frequently Asked Questions About Amplify Weight Loss Drug & Treatment ETF
What is the current price of THNR?
The latest THNR price is $24.50 (Oct 16, 2026 close). The 52-week range is $22.89–$27.94. The share price is up 5.9% over the past year (price change, excluding distributions).
What is the expense ratio for THNR?
THNR's annual expense ratio is 0.59%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.
Does THNR pay dividends?
Yes, THNR pays a 1.67% dividend yield (trailing 12 months, at the Oct 16, 2026 close). The most recent ex-dividend date was December 30, 2025. View full dividend history in the Dividends section.
What are the top holdings of THNR?
As of Oct 4, 2026, THNR's largest holdings are Eli Lilly and Company (10.2%), Novo Nordisk A/S (8.5%), CSPC Pharmaceutical Group Limited (5.9%) (combined weight: 24.6%). The fund holds 23 total positions. View the complete portfolio breakdown in the Holdings section.
How does THNR compare to similar ETFs?
Compare THNR (0.59% expense ratio, $6M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.